Therapeutic Benefit of Concurrent Radiation With Single Agent Nimotuzumab in Locally Advanced and Recurrent HNSCC: A Retrospective Analysis

Kondaveeti, Satish Srinivas; Sundaram, Raja

doi:10.1016/j.ijrobp.2014.05.1696

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings of improved survival benefit in recurrent and metastatic SCCHN are similar to survival benefit observed in LA-SCCHN setting. [ 18 20 25 26 27 28 29 30 ] The improved OS achieved with the addition of nimotuzumab to the standard treatment in the present analysis is higher than the documented landmark EXTREME cetuximab study. [ 17 ] Thus, nimotuzumab as an add-on to standard treatment can be a promising option in recurrent and metastatic SCCHN.…”

Section: Discussionmentioning

confidence: 67%

“…In India, several authors in their individual research have documented that the addition of nimotuzumab to various standard treatment/combined treatment strategies (RT or chemotherapy or concurrent chemoradiation) in LA-SCCHN improved tumor response rate and survival outcomes with minimal toxicities. [ 19 20 25 26 27 28 29 ] However, its role in recurrent and metastatic SCCHN setting is not well explored.…”

Section: Discussionmentioning

confidence: 99%

“…At present, the clinical efficacy and safety of nimotuzumab in LA-SCCHN are well established, and several authors have documented that the addition of the nimotuzumab to various standard treatments (RT or chemotherapy or CRT) improved the tumor response rate and survival with minimal toxicities in LA-SCCHN. [ 18 20 25 26 27 28 29 ]…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence

Subramanian¹,

Nithya²,

Balasundaram³

et al. 2018

South Asian J Cancer

View full text Add to dashboard Cite

Context:Role of nimotuzumab in locally advanced head and neck cancer (HNC) is well established in India; however, no clinical evidence is available for its role in recurrent and/or metastatic HNC.Aims:The aim of this study is to evaluate the efficacy and safety of nimotuzumab when added to standard treatment in unresectable, recurrent, and metastatic squamous cell carcinoma of the head and neck (SCCHN).Settings and Design:Hospital records of 14 patients diagnosed with recurrent and/or metastatic HNC with histologically confirmed squamous cell carcinoma and being treated with nimotuzumab along with standard treatments from December 2010 to December 2016 were retrospectively evaluated.Subjects and Methods:The tumor response rate and overall survival (OS) were analyzed. Toxicity and adverse events (AEs) were assessed as per common terminology criteria for adverse events (CTCAE) v 4.Results:Oral cavity was most commonly involved region followed by hypopharynx and oropharynx. At 24 weeks after completion of treatment, overall response rate (complete response (CR) + partial response (PR)) was 75%. Survival rate at 1, 2, and 3 years was 77.80%, 64.81%, and 64.81%, respectively. At a median follow-up of 15.17 months, median OS was not reached. All AEs were either Grade I (66.7%) or Grade II (33.3%). No Grade III or Grade IV AEs were observed. No added toxicity was observed due to nimotuzumab.Conclusions:In the first of its kind study, the addition of nimotuzumab to standard treatment showed promising response rate as well as survival outcomes in recurrent and/or metastatic SCCHN patients without producing additional toxicity.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence

Subramanian¹,

Nithya²,

Balasundaram³

et al. 2018

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

“…[14,[31][32][33][34][35][36][37][38] Similarly, Table 7 shows the published Indian data on nimotuzimab in SCCHN. [39][40][41][42][43][44][45][46][47] What are the efficacy differences between cetuximab and nimotuzumab?…”

Section: What Is the Clinical Implication Of Monovalent Binding With mentioning

confidence: 99%

Oncology gold standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck

Babu

Bahl

Bhattacharya

et al. 2017

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

Therapeutic Benefit of Concurrent Radiation With Single Agent Nimotuzumab in Locally Advanced and Recurrent HNSCC: A Retrospective Analysis

Cited by 2 publications

References 0 publications

Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence

Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence

Oncology gold standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck

Contact Info

Product

Resources

About